[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pyxis Oncology Inc (PYXS)

Pyxis Oncology Inc (PYXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 144,566
  • Shares Outstanding, K 62,855
  • Annual Sales, $ 13,860 K
  • Annual Income, $ -79,620 K
  • EBIT $ -82 M
  • EBITDA $ -80 M
  • 60-Month Beta 1.43
  • Price/Sales 8.30
  • Price/Cash Flow N/A
  • Price/Book 2.13

Options Overview Details

View History
  • Implied Volatility 141.18% (+12.35%)
  • Historical Volatility 101.84%
  • IV Percentile 6%
  • IV Rank 10.57%
  • IV High 907.78% on 01/20/26
  • IV Low 50.57% on 09/12/25
  • Expected Move (DTE 8) 0.09 (4.14%)
  • Put/Call Vol Ratio 0.03
  • Today's Volume 35
  • Volume Avg (30-Day) 153
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 4,053
  • Open Int (30-Day) 4,168
  • Expected Range 2.17 to 2.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.35
  • Number of Estimates 5
  • High Estimate $-0.31
  • Low Estimate $-0.40
  • Prior Year $-0.35
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.42 +57.04%
on 04/08/26
2.37 -5.91%
on 05/06/26
+0.77 (+52.74%)
since 04/07/26
3-Month
1.26 +76.98%
on 03/30/26
2.37 -5.91%
on 05/06/26
+0.72 (+47.68%)
since 02/06/26
52-Week
0.97 +129.90%
on 08/11/25
5.55 -59.82%
on 11/26/25
+1.16 (+108.41%)
since 05/07/25

Most Recent Stories

More News
Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

Mouse analog of MICVO (maMICVO) monotherapy produced dose-dependent inhibition of tumor growth in a syngeneic preclinical model of HNSCC maMICVO monotherapy modulated the tumor-immune environment...

PYXS : 2.23 (-3.04%)
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) in the first quarter...

PYXS : 2.23 (-3.04%)
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership...

PYXS : 2.23 (-3.04%)
The $537B Precision Pivot: Why Molecular Monitoring is the New Oncology Standard

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The war on cancer is moving into a high-tech era of molecular-guided defense. The genomics in cancer care...

ONCY : 0.8816 (-4.17%)
PYXS : 2.23 (-3.04%)
PSNL : 5.88 (-3.13%)
NBP : 2.17 (-3.56%)
TOI : 3.95 (+3.95%)
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO...

PYXS : 2.23 (-3.04%)
Pyxis Oncology to Participate in Upcoming Investor Conferences

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that management...

PYXS : 2.23 (-3.04%)
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results

-  Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the fourth...

PYXS : 2.23 (-3.04%)
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings

Translational data validate mechanism of first-in-concept extracellular-cleaving ADC micvotabart pelidotin (MICVO) MICVO combats solid tumors through three-pronged mechanism of action: direct tumor...

PYXS : 2.23 (-3.04%)
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets

BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced...

PYXS : 2.23 (-3.04%)
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) therapeutics for difficult-to-treat...

PYXS : 2.23 (-3.04%)

Business Summary

Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 3.06
2nd Resistance Point 2.71
1st Resistance Point 2.51
Last Price 2.23
1st Support Level 1.96
2nd Support Level 1.61
3rd Support Level 1.41

See More

52-Week High 5.55
Fibonacci 61.8% 3.80
Fibonacci 50% 3.26
Fibonacci 38.2% 2.72
Last Price 2.23
52-Week Low 0.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.